77 related articles for article (PubMed ID: 28506066)
1. De Novo Computational Design for Development of a Peptide Ligand Oriented to VEGFR-3 with High Affinity and Long Circulation.
Li HM; Dong ZP; Wang QY; Liu LX; Li BX; Ma XN; Lin MS; Lu T; Wang Y
Mol Pharm; 2017 Jul; 14(7):2236-2244. PubMed ID: 28506066
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel peptide ligand of human vascular endothelia growth factor receptor 3 for targeted tumour diagnosis and therapy.
Qin X; Wan Y; Li M; Xue X; Wu S; Zhang C; You Y; Wang W; Jiang C; Liu Y; Zhu W; Ran Y; Zhang Z; Han W; Zhang Y
J Biochem; 2007 Jul; 142(1):79-85. PubMed ID: 17517791
[TBL] [Abstract][Full Text] [Related]
3. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
4. Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor.
Marquez BV; Ikotun OF; Parry JJ; Rogers BE; Meares CF; Lapi SE
J Nucl Med; 2014 Jun; 55(6):1029-34. PubMed ID: 24732153
[TBL] [Abstract][Full Text] [Related]
5. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R
Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147
[TBL] [Abstract][Full Text] [Related]
6. Identification of high-affinity VEGFR3-binding peptides through a phage-displayed random peptide library.
Shi LF; Wu Y; Li CY
J Gynecol Oncol; 2015 Oct; 26(4):327-35. PubMed ID: 26197772
[TBL] [Abstract][Full Text] [Related]
7. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Nock BA; Maina T; Krenning EP; de Jong M
J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
[TBL] [Abstract][Full Text] [Related]
8. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
[TBL] [Abstract][Full Text] [Related]
9. PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.
Luo H; England CG; Graves SA; Sun H; Liu G; Nickles RJ; Cai W
J Nucl Med; 2016 Feb; 57(2):285-90. PubMed ID: 26541778
[TBL] [Abstract][Full Text] [Related]
10. Anticalins directed against vascular endothelial growth factor receptor 3 (VEGFR-3) with picomolar affinities show potential for medical therapy and in vivo imaging.
Richter A; Skerra A
Biol Chem; 2017 Jan; 398(1):39-55. PubMed ID: 27458663
[TBL] [Abstract][Full Text] [Related]
11. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.
Li F; Jiang S; Zu Y; Lee DY; Li Z
J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer.
Okarvi SM; Jammaz IA
Anticancer Res; 2009 Apr; 29(4):1399-409. PubMed ID: 19414394
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
Garces CA; Kurenova EV; Golubovskaya VM; Cance WG
Cancer Res; 2006 Feb; 66(3):1446-54. PubMed ID: 16452200
[TBL] [Abstract][Full Text] [Related]
15. Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity.
Alam A; Herault JP; Barron P; Favier B; Fons P; Delesque-Touchard N; Senegas I; Laboudie P; Bonnin J; Cassan C; Savi P; Ruggeri B; Carmeliet P; Bono F; Herbert JM
Biochem Biophys Res Commun; 2004 Nov; 324(2):909-15. PubMed ID: 15474514
[TBL] [Abstract][Full Text] [Related]
16. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
[TBL] [Abstract][Full Text] [Related]
17. A new PET tracer specific for vascular endothelial growth factor receptor 2.
Wang H; Cai W; Chen K; Li ZB; Kashefi A; He L; Chen X
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2001-10. PubMed ID: 17694307
[TBL] [Abstract][Full Text] [Related]
18. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
[TBL] [Abstract][Full Text] [Related]
19. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
